Search Results for "Metabolic"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Metabolic. Results 351 to 360 of 1047 total matches.

In Brief: One Drop or Two

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 2006  (Issue 1237)
may inhibit the metabolism and might increase the toxicity of tricyclic antidepressants (TCAs) and selective ...
Many prescriptions for eye drops call for instillation of 1-2 drops. But Medical Letter consultants in ophthalmology seem to agree that all eye drops should generally be given in doses of only one drop. The volume of a single drop can vary with the viscosity of the solution, the design of the dropper, and patient technique. The average volume of a drop is 35-50 microliters, but can be as high as 75 microliters. An eye brimming with fluid holds 30 microliters at best, so even one drop is often an overdose. A second either washes out the first or increases the possibility of systemic toxicity,...
Med Lett Drugs Ther. 2006 Jun 19;48(1237):49 |  Show IntroductionHide Introduction

Idarubicin

   
The Medical Letter on Drugs and Therapeutics • Sep 06, 1991  (Issue 852)
may increase cellular uptake compared to other anthracyclines. The drug is metabolized in the liver ...
Idarubicin hydrochloride (Idamycin - Adria), an anthracycline structurally related to daunorubicin (Cerubidine, and others) and doxorubicin (Adriamycin, and others), was recently approved in the USA for treatment of acute myelogenous leukemia (AML) in adults.
Med Lett Drugs Ther. 1991 Sep 6;33(852):84-5 |  Show IntroductionHide Introduction

Mivacurium - A New Neuromuscular Blocker

   
The Medical Letter on Drugs and Therapeutics • Aug 21, 1992  (Issue 877)
, 1989). Like succinylcholine, mivacurium is metabolized by plasma cholinesterase, and the duration ...
Mivacurium chloride (Mivacron - Burroughs-Wellcome), a short-acting nondepolarizing neuromuscular blocking drug, is now available in the USA for intravenous use in routine intubation and short procedures requiring skeletal muscle relaxation. It can be given in a bolus or a continuous infusion.
Med Lett Drugs Ther. 1992 Aug 21;34(877):82 |  Show IntroductionHide Introduction

Crizotinib (Xalkori) for Non-Small Cell Lung Cancer

   
The Medical Letter on Drugs and Therapeutics • Feb 06, 2012  (Issue 1383)
concentrations of drugs that are metabolized by these pathways. It is also a substrate of CYP3A4. Inhibitors ...
The FDA has approved crizotinib (Xalkori – Pfizer), an oral tyrosine kinase inhibitor, for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with the anaplastic lymphoma kinase (ALK) translocation, which is found in about 4-5% of lung cancers. A diagnostic test (Vysis ALK Break Apart FISH Probe Kit – Abbott Molecular) is available to detect translocations of the ALK gene in tumor samples; these translocations occur predominantly in nonsmokers with adenocarcinoma.
Med Lett Drugs Ther. 2012 Feb 6;54(1383):11-2 |  Show IntroductionHide Introduction

Regorafenib (Stivarga) for Metastatic Colorectal Cancer and GIST (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 2013  (Issue 1415)
is metabolized by CYP3A4 and UGT1A9 to 2 main active metabolites. Coadministration with the strong CYP3A4 ...
Regorafenib (Stivarga – Bayer), a multikinase inhibitor, has been approved by the FDA for treatment of patients with metastatic colorectal cancer previously treated with multiple other regimens specified in the labeling. It has also been approved for use in treatment-refractory, locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST).
Med Lett Drugs Ther. 2013 Apr 29;55(1415):36 |  Show IntroductionHide Introduction

Drugs for Osteoarthritis

   
The Medical Letter on Drugs and Therapeutics • Apr 20, 2020  (Issue 1596)
dose should be reduced by 50% in patients who are CYP2C9 poor metabolizers. 10. The maximum ...
Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Nonpharmacologic approaches including weight management, exercise, tai chi, physical therapy, assistive devices, and total joint arthroplasty can also be used. The American College of Rheumatology (ACR) has published new guidelines for the management of osteoarthritis of the hip, hand, and knee.
Med Lett Drugs Ther. 2020 Apr 20;62(1596):57-62 |  Show IntroductionHide Introduction

Drugs for Helicobacter pylori Infection

   
The Medical Letter on Drugs and Therapeutics • Jul 17, 2017  (Issue 1525)
that are metabolized by these pathways.36 Taking clarithromycin with other drugs that prolong the QT interval ...
About 50% of the world’s population is infected with Helicobacter pylori. These gastric bacteria can cause chronic inflammation and have been associated with development of gastritis, peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Eradication of H. pylori can promote gastric healing, prevent recurrence of duodenal and gastric ulcers, and reduce the incidence of gastric cancer. Guidelines for treatment of H. pylori infection were updated recently.
Med Lett Drugs Ther. 2017 Jul 17;59(1525):113-7 |  Show IntroductionHide Introduction

Rasagiline (Azilect) for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Dec 04, 2006  (Issue 1249)
have demonstrated neuroprotective and anti-apoptotic effects on dopamine neurons. Selegiline is metabolized ...
Rasagiline (Azilect - Teva), a monoamine oxidase-type B (MAO-B) inhibitor, was recently approved by the FDA for once-daily oral treatment of Parkinson's disease (PD). It can be taken alone for treatment of early disease or with levodopa/carbidopa (Sinemet, and others) for advanced disease. Selegiline (Eldepryl, and others), the first MAO-B inhibitor marketed in the US, has been available since 1988; a new lower-dose disintegrating tablet (Zelapar) was recently approved.
Med Lett Drugs Ther. 2006 Dec 4;48(1249):97-9 |  Show IntroductionHide Introduction

Vinorelbine For Treatment of Advanced Non-Small-Cell Lung Cancer

   
The Medical Letter on Drugs and Therapeutics • Aug 18, 1995  (Issue 955)
— Vinorelbine is metabolized in the liver and excreted mostly in bile. About 20% of the dose appears in urine ...
Vinorelbine (Navelbine - Burroughs Wellcome), a semisynthetic vinca alkaloid, has been approved by the US Food and Drug Administration for parenteral use in the treatment of advanced non-small-cell lung cancer (NSCLC). Various combinations of cisplatin (Platinol), vinblastine (Velban, and others), mitomycin (Mutamycin), ifosfamide (Ifex), etoposide (VePesid) and paclitaxel (Taxol) have been used previously for this indication.
Med Lett Drugs Ther. 1995 Aug 18;37(955):72-3 |  Show IntroductionHide Introduction

St. John's Wort

   
The Medical Letter on Drugs and Therapeutics • Nov 21, 1997  (Issue 1014)
days. Whether it is metabolized and how it is excreted are unknown. The half-life of hypericin ...
Many readers have asked the Medical Letter to evaluate St. John's wort, an herbal extract now widely sold in health food stores and pharmacies, for its effectiveness and safety in the treatment of depression. St. John's wort is licensed in Germany for treatment of anxiety, depression and insomnia. In the USA, it is considered a dietary supplement and has not been evaluated by the FDA.
Med Lett Drugs Ther. 1997 Nov 21;39(1014):107-8 |  Show IntroductionHide Introduction